These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 22623266

  • 1. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB.
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [Abstract] [Full Text] [Related]

  • 2. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.
    Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB.
    Br J Pharmacol; 2011 Sep; 164(2b):433-43. PubMed ID: 21449914
    [Abstract] [Full Text] [Related]

  • 3. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A, Spina E, Dahl ML, Scordo MG.
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [Abstract] [Full Text] [Related]

  • 4. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM.
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [Abstract] [Full Text] [Related]

  • 5. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM.
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
    Sherwin CM, Saldaña SN, Bies RR, Aman MG, Vinks AA.
    Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
    [Abstract] [Full Text] [Related]

  • 7. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, Ono S, Saito M, Someya T.
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A, Piotrovsky V, Ludwig EA.
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [Abstract] [Full Text] [Related]

  • 9. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L, Trkulja V, Živković M, Božina T, Šagud M, Lovrić M, Božina N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan 10; 104():110042. PubMed ID: 32682874
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
    Ding JJ, Jiao Z, Yu YQ, Shi XJ.
    Yao Xue Xue Bao; 2007 Jun 10; 42(6):631-8. PubMed ID: 17702401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB.
    Clin Pharmacokinet; 2015 Dec 10; 54(12):1259-72. PubMed ID: 26129906
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
    Cho HY, Lee YB.
    Arch Pharm Res; 2006 Jun 10; 29(6):525-33. PubMed ID: 16833023
    [Abstract] [Full Text] [Related]

  • 15. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants.
    Schoretsanitis G, de Leon J, Diaz FJ.
    Pharmacogenomics; 2018 Jul 01; 19(10):815-823. PubMed ID: 29914302
    [Abstract] [Full Text] [Related]

  • 16. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
    Novalbos J, López-Rodríguez R, Román M, Gallego-Sandín S, Ochoa D, Abad-Santos F.
    J Clin Psychopharmacol; 2010 Oct 01; 30(5):504-11. PubMed ID: 20814331
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, de Vries R, Kaneko S.
    Ther Drug Monit; 2003 Jun 01; 25(3):287-93. PubMed ID: 12766554
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD, Cho HY, Lee YB.
    Br J Clin Pharmacol; 2010 Jan 01; 69(1):27-37. PubMed ID: 20078610
    [Abstract] [Full Text] [Related]

  • 20. Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo.
    Størset E, Bråten LS, Ingelman-Sundberg M, Johansson I, Molden E, Kringen MK.
    Eur J Clin Pharmacol; 2024 Oct 01; 80(10):1531-1541. PubMed ID: 38963454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.